In the third quarter, Pfizer experienced a remarkable boost in revenue, primarily driven by robust sales of its COVID-19 treatment, Paxlovid, alongside growth from several other pharmaceuticals. The drugmaker reported a total revenue of $17.7 billion for the quarter, marking a significant increase of 31% compared to the previous year. Paxlovid alone generated $2.7 billion...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
